Nora Therapeutics Is Hoping To Teach An Old Dog New Tricks In Fertility
This article was originally published in Start Up
Having raised an $18 million Series B, Nora is continuing a Phase II trial of lead G-CSF candidate NT100 in IVF failure. But the biotech also has begun enrolling a second Phase II study in women with unexplained recurrent miscarriage.
You may also be interested in...
Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier
To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.